資料2

アンチバイオグラム
地域別2023

Escherichia coli 大腸菌
Klebsiella pneumoniae subsp. Pneumoniae
クレブシエラ菌
Streptococcus pneumoniae 肺炎球菌（髄液検体以外）
Streptococcus pyogenes 溶連菌
Haemophilus influenzae インフルエンザ菌
Staphylococcus aureus 黄色ブドウ球菌 (耐性比率)

全国データは、JANIS （Japan Nosocomial Infections Surveillance 厚生労働省院内感染対策サーベイランス事業）の資料に基づいたものです

S：感受性、I：中間、R：耐性、NS：非感受性

腸内細菌目細菌の固有耐性

CLSI M100-ED33:2023 Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edition より引用

Antimicrobial Agent → / Organism ↓	Ampicillin	Amoxicillin-clavulanate	Ampicillin-sulbactam	Ticarcillin	Cephalosporins I: Cefazolin, Cephalothin	Cephamycins: Cefoxitin, Cefotetan	Cephalosporin II: Cefuroxime	Imipenem	Tetracyclines	Tigecycline	Nitrofurantoin	Polymyxin B Colistin	Aminoglycosides
Citrobacter freundii	R	R	R		R	R	R						
Citrobacter koseri, *Citrobacter amalonaticus* group[a]	R			R									
Enterobacter cloacae complex[b]	R	R	R		R	R							
Escherichia coli	There is no intrinsic resistance to β-lactams in this organism.												
Escherichia hermannii	R			R									
Hafnia alvei	R	R	R		R	R						R[c]	
Klebsiella (formerly *Enterobacter*) *aerogenes*	R	R	R		R	R							
Klebsiella pneumoniae, *Klebsiella oxytoca*, *Klebsiella variicola*	R			R									
Morganella morganii	R	R			R		R	[d]		R	R	R	
Proteus mirabilis	There is no intrinsic resistance to penicillins and cephalosporins in this organism.							[d]	R	R	R	R	
Proteus penneri	R				R		R	[d]	R	R	R	R	
Proteus vulgaris	R				R		R	[d]	R	R	R	R	
Providencia rettgeri	R	R			R			[d]	R	R	R	R	
Providencia stuartii	R	R			R			[d]	R	R	R	R	[e]
Raoultella spp.[f]	R			R									
Salmonella and *Shigella* spp.	There is no intrinsic resistance to β-lactams in these organisms; refer to **WARNING** below for reporting.												
Serratia marcescens	R	R	R		R	R	R				R	R	[g]
Yersinia enterocolitica	R	R		R	R								

Abbreviations: MIC, minimal inhibitory concentration; R, resistant.

WARNING: For *Salmonella* spp. and *Shigella* spp., aminoglycosides, first- and second-generation cephalosporins, and cephamycins may appear active *in vitro* but are not effective clinically and should not be reported as susceptible.

Footnotes

a. *Citrobacter amalonaticus* group includes *C. amalonaticus*, *C. farmeri*, and *C. sedlakii*.

b. *E. cloacae* complex includes *Enterobacter asburiae*, *Enterobacter cloacae*, and *Enterobacter hormaechei*. Other members of the complex include *Enterobacter kobei* and *Enterobacter ludwigii*, for which antimicrobial susceptibility testing data are not available.

c. Colistin and polymyxin B resistance also applies to *Hafnia paralvei*.

d. *Proteus* spp., *Providencia* spp., and *Morganella* spp. may have elevated minimal inhibitory concentrations to imipenem by mechanisms other than by production of carbapenemases. Isolates that test as susceptible should be reported as susceptible.

e. *P. stuartii* should be considered resistant to gentamicin, netilmicin, and tobramycin but not intrinsically resistant to amikacin.

f. *Raoultella* spp. includes *R. ornithinolytica*, *R. terrigena*, and *R. planticola*.

g. *Serratia marcescens* may have elevated MICs to tobramycin. Isolates that test susceptible should be reported as susceptible.

NOTE 1: Cephalosporins III, cefepime, cefiderocol, aztreonam, ticarcillin-clavulanate, piperacillin-tazobactam, imipenem-relebactam, ceftazidime-avibactam, meropenem-vaborbactam, and the carbapenems are not listed because there is no intrinsic resistance in Enterobacterales.

NOTE 2: Enterobacterales are also intrinsically resistant to clindamycin, daptomycin, fusidic acid, glycopeptides (vancomycin), lipoglycopeptides (oritavancin, teicoplanin, telavancin), linezolid, tedizolid, quinupristin-dalfopristin, rifampin, and macrolides (erythromycin, clarithromycin, and azithromycin). However, there are some exceptions with macrolides (eg, *Salmonella* and *Shigella* spp. with azithromycin).

NOTE 3: Information in black boldface type is new or modified since the previous edition.

【データ収集期間】

2023年1月から3月までの3ヶ月間（入院・外来検体）の菌株数

JANISデータは2022年（外来検体）と比較した

【データ提供医療機関数】

東部	15施設（クリニック 3施設）	6401株
中部	16施設（クリニック 3施設）	11866株
西部	15施設	8701株
合計	46施設（クリニック 6施設）	26968株

	菌名	西部	中部	東部	総計
1	*Escherichia coli*	1416	2200	987	4603
2	*Staphylococcus aureus* (MSSA)	943	1095	565	2603
3	*Pseudomonas aeruginosa*	570	809	488	1867
4	*Staphylococcus aureus* (MRSA)	628	860	375	1863
5	*Klebsiella pneumoniae subsp. pneumoniae*	526	810	457	1793
6	*Enterococcus faecalis*	440	485	382	1307
8	Staphylococcus epidermidis	378	295	223	896
9	*Streptococcus agalactiae*	319	308	231	858
10	*Klebsiella oxytoca*	186	254	155	595
11	*Corynebacterium spp.*	124	198	243	565
12	*Enterococcus faecium*	198	235	128	561
13	*Proteus mirabilis*	94	233	141	468
14	*Enterobacter cloacae*	132	167	107	406
15	*Staphylococcus spp.*	47	242	105	394
16	*Klebsiella aerogenes*	104	162	98	364
18	*Haemophilus influenzae*	183	106	43	332
19	*Serratia marcescens*	63	163	96	322
20	*Streptococcus spp.*	223	42	52	317
21	*Streptococcus anginosus*	133	79	34	246
22	*Streptococcus pneumoniae*	88	92	38	218
31	*Enterococcus faecium* (VRE)			127	127
36	*Moraxella (Branhamella) catarrhalis*	26	66	22	114
47	*Streptococcus pyogenes*	23	24	12	59

【*Escherichia coli*】 大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】 大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】 大腸菌

S:感受性、I :中間、R:耐性、NS:非感受性





CLSI M100-ED33:2023 Performance Standards for Antimicrobial Susceptibility Testing, 33rd Editionでは、大腸菌に対するFOMの判定基準は、UTIのみに設定されています。

【 *Klebsiella pneumoniae subsp. pneumoniae*】 クレブシエラ菌

S：感受性、I ：中間、R：耐性、NS：非感受性







【 *Klebsiella pneumoniae* 】　クレブシエラ菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pneumoniae*（髄液検体以外）】 肺炎球菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pneumoniae* (髄液検体以外)】肺炎球菌

S:感受性、I:中間、R:耐性、NS:非感受性







【 *Streptococcus pyogenes* 】溶連菌

S:感受性、I:中間、R:耐性、NS:非感受性







【 *Streptococcus pyogenes*】溶連菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I ：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I：中間、R：耐性、NS：非感受性



【 *Staphylococcus aureus* 】 黄色ブドウ球菌
静岡県2023年1−3月期とJANIS2022年との比較



【 バンコマイシン耐性MRSA 患者数】
なし

【 VCM非感受性*Enterococcus faecium* /*Enterococcus faecalis*(VRE) （患者数）】
E. faecium

東部	81名	6施設
中部	1名	1施設